Evan Yu presents OMAHA-003, testing opevesostat, a CYP11A1 antagonist targeting one step earlier than abiraterone in steroid biosynthesis. The drug eliminates mineralocorticoids and cortisol alongside ...
The 2026 ASCO GU Annual Symposium was host to a trials-in-progress prostate cancer poster session. Dr. Umang Swami presented ...
The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...
The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for ...
The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...
Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinoma (LG-UTUC): A single-arm, open-label phase 1/2 ...
Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...
Based on the NCCN 1.2026 guidelines for the management of CSI seminoma, surveillance is strongly preferred for pT1-pT3 tumors, and the NCCN does not recommend risk-adapted treatment for CSI seminoma ...
(UroToday.com) The 2026 GU ASCO annual meeting featured an innovations in kidney cancer in 2026 session and a presentation by Dr. Michael Hofman discussing emerging tools in imaging in renal cell ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Tian Zhang outlines management strategies for patients progressing from metastatic hormone-sensitive to castration-resistant prostate cancer with upfront expectation-setting discussions. Dr. Zhang ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results